Eligo Bioscience

Eligo Bioscience was founded in 2014 as a spin-off from MIT and the Rockefeller University based on the discoveries from the Lu and Marraffini labs. The company develops a new generation of biotherapeutics that enable the expression of genetic circuits within target microbial populations and treat a wide-range of bacteria-associated unmet medical needs both in humans and animals. The company has won several international awards, has raised a US$3M seed-round in July 2015 and is currently located at Institut Pasteur in the heart of Paris.

访问 Eligo Bioscience 网站

关于我们

加入我们

  • 登录
  • 成为我们的合作伙伴
  • 成为我们的会员
  • 订阅我们的新闻稿
  • 联系我们

快捷链接

语言版本

隐私政策和服务条款

站点地图

© 2025 世界经济论坛